导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.90% | 1143/4773 |
| 近一周 | -0.77% | 1849/5467 |
| 近一月 | -4.90% | 2007/5421 |
| 近一季 | -6.27% | 2003/5238 |
| 近半年 | -1.11% | 1859/4931 |
| 近一年 | 7.91% | 1234/4400 |
| 近两年 | 63.80% | 1131/2954 |
| 近三年 | 33.82% | 932/2253 |
| 成立以来 | 170.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.90% 1143/4961 |
15.62% 1651/5312 |
- - |
- - |
| 2025 | 24.91% 1754/4813 |
2.71% 1285/3635 |
1.25% 2406/4076 |
20.71% 1934/4524 |
-0.49% 2515/4813 |
| 2024 | 6.20% 1782/3463 |
-1.63% 1251/2808 |
-2.41% 1186/3014 |
12.14% 2406/3129 |
-1.36% 1666/3463 |
| 2023 | -5.22% 723/2656 |
6.27% 703/2280 |
-3.55% 829/2385 |
-3.04% 836/2515 |
-4.63% 1119/2655 |
| 2022 | -15.96% 443/2207 |
-13.01% 684/1919 |
5.17% 935/2016 |
-9.37% 273/2113 |
1.35% 1292/2208 |
| 2021 | 23.43% 130/1822 |
0.10% 316/1255 |
10.86% 428/1330 |
6.84% 207/1466 |
4.11% 367/1822 |
| 2020 | 26.02% 610/1250 |
-4.54% 373/1028 |
16.82% 410/1067 |
8.50% 711/1164 |
4.15% 862/1184 |
| 2019 | 31.26% 472/1092 |
31.08% 215/754 |
-7.33% 552/804 |
1.70% 370/850 |
6.26% 637/918 |
| 2018 | -29.18% 447/834 |
- - |
- - |
- - |
-13.18% 513/691 |
| 2017 | 4.54% 392/714 |
- - |
- - |
- - |
- - |
| 2016 | -16.41% 373/605 |
- - |
- - |
- - |
- - |
| 2015 | 38.26% 49/575 |
- - |
- - |
- - |
- - |
| 2014 | 44.86% 109/237 |
- - |
- - |
- - |
- - |
| 2013 | 14.31% 32/186 |
- - |
- - |
- - |
- - |
| 2012 | -1.05% 126/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 港股通医疗ETF工银 | 0.9798 | 32.23% |
| 港股通医疗ETF华宝 | 0.9918 | 32.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.9074 | 30.77% |
| 永赢中证港股通医疗主题ETF发起联接C | 0.9055 | 30.72% |
| 嘉实中证港股通创新药指数发起式A | 0.8665 | 30.57% |
| 南方上证380ETF VS. 长安沪深300非周期A(740101) |